Stephen Archer to Antihypertensive Agents
This is a "connection" page, showing publications Stephen Archer has written about Antihypertensive Agents.
Connection Strength
1.944
-
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. J Am Heart Assoc. 2019 01 08; 8(1):e011343.
Score: 0.557
-
Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 2010 Nov; 138(5):1234-9.
Score: 0.316
-
Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep. 2010 Feb; 12(1):8-18.
Score: 0.300
-
An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol. 2006 Jul; 21(4):385-92.
Score: 0.234
-
Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. J Am Heart Assoc. 2021 07 20; 10(14):e021518.
Score: 0.166
-
Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018 02; 11(2):e003973.
Score: 0.131
-
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res. 2012 May 25; 110(11):1484-97.
Score: 0.087
-
Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. Int J Clin Pract Suppl. 2011 Aug; (172):15-34.
Score: 0.083
-
Case 2. Recurrence of myocardial infarction. Can J Cardiol. 2000 Aug; 16 Suppl E:24E-26E.
Score: 0.039
-
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619.
Score: 0.018
-
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006 Nov; 13(21):1503-11.
Score: 0.015